Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Wilex Rencarex Phase III Result Shows No Efficacy

FDAnews Drug Daily Bulletin

Oct. 29, 2012 | Vol. 9 No. 212

Wilex Rencarex Phase III Result Shows No Efficacy

Redectane and Mesupron are now Wilex’s key products after the Rencarex Phase III ARISER data showed no efficacy; Rencarex has been discontinued.
ForexPros

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch Distributor’s Threat on Drug Deliveries Breakup of Physician, Drug Company Relationship Could Improve Healthcare, Cut Cost European Pharmacist Organizations Call for Action By Governments to Tackle Shortages

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.